[1]吴桂平,吴海燕,王文娟,等.白癜风患者外周血单个核细胞CXC趋化因子配体10、CXC趋化因子受体3表达水平及检测意义[J].陕西医学杂志,2024,(11):1500-1503,1507.[doi:DOI:10.3969/j.issn.1000-7377.2024.11.013]
　WU Guiping,WU Haiyan,WANG Wenjuan,et al.Expression and significance of CXC chemokine ligand-10 and CXC chemokine ligand receptor-3 in peripheral blood mononuclear cells of patients with vitiligo[J].,2024,(11):1500-1503,1507.[doi:DOI:10.3969/j.issn.1000-7377.2024.11.013]
点击复制

白癜风患者外周血单个核细胞CXC趋化因子配体10、CXC趋化因子受体3表达水平及检测意义
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2024年11期
页码:
1500-1503,1507
栏目:
临床研究
出版日期:
2024-11-05

文章信息/Info

Title:
Expression and significance of CXC chemokine ligand-10 and CXC chemokine ligand receptor-3 in peripheral blood mononuclear cells of patients with vitiligo
作者:
吴桂平; 吴海燕; 王文娟; 胡杏林; 蒋小音
(郴州市第一人民医院,湖南 郴州 423000)
Author(s):
WU Guiping; WU Haiyan; WANG Wenjuan; HU Xinglin; JIANG Xiaoyin
(The First People's Hospital of Chenzhou,Chenzhou 423000,China)
关键词:
白癜风;  趋化因子配体10;  趋化因子受体3;  临床特征;  复发风险;  预测价值
Keywords:
Vitiligo;  CXC chemokine ligand-10;  CXC chemokine ligand receptor-3;  Clinical features;  Recurrence risk;  Predictive value
分类号:
R 758.41
DOI:
DOI:10.3969/j.issn.1000-7377.2024.11.013
文献标志码:
A
摘要:
目的:探究白癜风患者外周血单个核细胞(PBMC)中CXC趋化因子配体10(CXCL10)、CXC趋化因子受体3(CXCR3)的表达水平及检测意义。方法:选取收治的白癜风患者120例为观察组,另选取同期性别、年龄相匹配的体检健康者120例为对照组。比较两组PBMC中CXCL10、CXCR3 mRNA表达水平,分析PBMC中CXCL10、CXCR3 mRNA表达与白癜风患者临床特征的关系。统计患者复发情况,并分为复发组(55例)和未复发组(65例)。比较复发组和未复发组患者PBMC中CXCL10/CXCR3 mRNA表达水平。评价PBMC中CXCL10、CXCR3 mRNA对白癜风患者复发风险的预测价值。结果:观察组PBMC中CXCL10及CXCR3 mRNA表达水平高于对照组(均P<0.05)。患者PBMC中CXCL10、CXCR3 mRNA表达水平在不同疾病分期、皮损面积及病程方面比较差异有统计学意义(均P<0.05)。PBMC中CXCL10、CXCR3 mRNA表达与患者疾病分期、皮损面积及病程呈正相关(均P<0.05)。复发组患者PBMC中CXCL10、CXCR3 mRNA表达水平高于未复发组(均P<0.05)。PBMC中CXCL10、CXCR3 mRNA以及两者联合预测白癜风患者复发风险的AUC分别为0.781、0.754、0.934,且两者联合预测的AUC高于各指标单独预测的AUC(均P<0.05)。结论:白癜风患者PBMC中CXCL10及CXCR3 mRNA表达水平升高,与疾病分期、皮损面积、病程有关,且两者联合对白癜风患者复发风险的预测价值较高。
Abstract:
Objective:To investigate the expression levels of CXC chemokine ligand-10(CXCL10)and CXC chemokine ligand receptor-3(CXCR3)in peripheral blood mononuclear cells(PBMC)of patients with vitiligo and their detection significance.Methods:A total of 120 patients with vitiligo were selected as the observation group,and another 120 healthy individuals matched for age and gender from the same period were selected as the control group.The mRNA expression levels of CXCL10 and CXCR3 in PBMC were compared between the two groups,and the relationship between the expression of CXCL10 and CXCR3 mRNA in PBMC and the clinical characteristics of vitiligo patients was analyzed.The recurrence status of patients was recorded,and they were divided into a recurrence group(55 cases)and a non-recurrence group(65 cases).The mRNA expression levels of CXCL10 and CXCR3 in PBMC were compared between the recurrence and non-recurrence groups.The predictive value of CXCL10 and CXCR3 mRNA in PBMC for the risk of recurrence in patients with vitiligo was evaluated.Results:The mRNA expression levels of CXCL10 and CXCR3 in PBMC were higher in the observation group than in the control group(all P<0.05).The expression levels of CXCL10 and CXCR3 mRNA in PBMC differed significantly among different stages of the disease,lesion area and disease duration(all P<0.05).The expression of CXCL10 and CXCR3 mRNA in PBMC was positively correlated with the disease stage,lesion area and disease duration of the patients(all P<0.05).The mRNA expression levels of CXCL10 and CXCR3 in PBMC were higher in the recurrence group than in the non-recurrence group(all P<0.05).The AUC of CXCL10,CXCR3 mRNA and their combination in predicting the recurrence risk of patients with vitiligo were 0.781,0.754 and 0.934,respectively,and the AUC of their combined prediction was higher than that of each index alone(all P<0.05).Conclusion:The mRNA expression levels of CXCL10 and CXCR3 in PBMC are elevated in patients with vitiligo and are associated with disease stage,lesion area and disease duration.The combined detection of both markers has a high predictive value for the risk of recurrence in patients with vitiligo.

参考文献/References:

[1] ROSMARIN D,PASSERON T,PANDYA A G,et al.Two phase 3,randomized,controlled trials of ruxolitinib cream for vitiligo[J].N Engl J Med,2022,387(16):1445-1455.
[2] 王远红,孟羽茜,王绍莹.基于“重寒伤肺”理论探讨阳虚型白癜风的证治[J].陕西中医,2023,44(6):762-765.
[3] HUSSAIN I.The safety of medicinal plants used in the treatment of vitiligo and hypermelanosis:A systematic review of use and reports of harm[J].Clin Cosmet Investig Dermatol,2021,14:261-284.
[4] BRAHIMABADI M H,LAMARDI S N S,SHIRBEIGI L.Immunomodulatory effects of medicinal plants used for vitiligo in traditional persian medicine[J].Curr Drug Discov Technol,2021,18(2):160-178.
[5] ARORA N,SIDDIQUI E M,MEHAN S.Involvement of adenylate cyclase/cAMP/CREB and SOX9/MITF in melanogenesis to prevent vitiligo[J].Mol Cell Biochem,2021,476(3):1401-1409.
[6] 满斯亮,张丽丽,孙琳,等.趋化因子CXCL10(IP-10)/CXCR3在类风湿关节炎发病中的作用及应用前景[J].中华老年多器官疾病杂志,2011,10(5):460-464.
[7] 吴联专,陈宠,郑贤干,等.儿童自身免疫性甲状腺炎患者血清趋化因子CXCL10及其受体CXCR3的变化及其临床意义[J].中国基层医药,2014,21(2):259-261.
[8] BONIFACE K,JACQUEMIN C,DARRIGADE A S,et al.Vitiligo skin is imprinted with resident memory CD8 T cells expressing CXCR3[J].J Invest Dermatol,2018,138(2):355-364.
[9] WANG X X,WANG Q Q,WU J Q,et al.Increased expression of CXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinical marker for vitiligo[J].Br J Dermatol,2016,174(6):1318-1126.
[10] 中国中西医结合学会皮肤性病专业委员会色素病学组.白癜风诊疗共识(2018版)[J].中华皮肤科杂志,2018,51(4):247-250.
[11] 李强,丁明,刘丹,等.白癜风复发因素回顾性调查与统计分析[J].临床皮肤科杂志,2021,50(2):81-84.
[12] KRIDIN K,GORAL D,SHIHADE W,et al.Vitiligo and Crohn's disease form an autoimmune cluster:Insights from a population-based study[J].Scand J Gastroenterol,2023,58(4):354-359.
[13] INOUE S,KATAYAMA I,SUZUKI T,et al.Rhododendrol-induced leukoderma update Ⅱ:Pathophysiology,mechanisms,risk evaluation,and possible mechanism-based treatments in comparison with vitiligo[J].J Dermatol,2021,48(7):969-978.
[14] 耿春杰,寇晓丽,黄俊会,等.清热凉血法联合加味乌藜消白汤治疗白癜风临床研究[J].陕西中医,2021,42(8):1028-1031,1036.
[15] RICHMOND J M,STRASSNER J P,ZAPATA L J R,et al.Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo[J].Sci Transl Med,2018,10(450):7710-7719.
[16] 李茜,欧阳洪,韩敬端,等.基于IFN-γ/JAK1/CXCL10信号通路探讨火针治疗稳定期白癜风的作用机制[J].现代中西医结合杂志,2023,32(17):2371-2377,2423.
[17] 赵艳霞,鲁娜,王璇,等.白癜风免疫学发病机制的探讨[J].中国中西医结合皮肤性病学杂志,2022,21(4):381-383.
[18] 朱芳丽,马厉英,马晓莹,等.急性胰腺炎患者血清CXC趋化因子配体10和CC类趋化因子22水平与疾病严重程度关系及临床诊断价值研究[J].陕西医学杂志,2024,53(6):788-792.
[19] 杨谦,曹冰清,韩征,等.CXC趋化因子配体10在癫痫大鼠和细胞炎症反应中的作用及机制研究[J].陕西医学杂志,2022,51(12):1483-1487.
[20] 白景芝,王利,王坤坤,等.IL-17和CXCL10及血清免疫球蛋白在类风湿关节炎合并感染患者鉴别诊断中的临床价值[J].中华医院感染学杂志,2022,32(16):2479-2482.
[21] HOJMAN L,CABRERA R,KARSULOVIC C,et al.The role of CXCL10 and IL-18 as markers of repigmentation response in nonsegmental vitiligo treated with narrowband UVB phototherapy:A prospective cohort study[J].J Invest Dermatol,2021,141(7):1833-1836.
[22] RASHIGHI M,AGARWAL P,RICHMOND J M,et al.CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo[J].Sci Transl Med,2014,6(223):223-233.
[23] 韩宪伟,马贤德,李铁男.儿童白癜风外周血单个核细胞中CXC趋化因子10、趋化因子受体3及干扰素-γ表达研究[J].临床皮肤科杂志,2020,49(6):334-338.
[24] NICOLAIDOU E,ANTONIOU C,STRATIGOS A J,et al.Efficacy,predictors of response,and long-term follow-up in patients with vitiligo treated with narrowband UVB phototherapy[J].J Am Acad Dermatol,2007,56(2):274-278.
[25] 张丽娜,吕超,王鑫,等.白癜风二氧化碳点阵激光联合复方倍他米松疗程中免疫炎症因子动态观测及与复发相关性[J].河北医科大学学报,2023,44(12):1460-1466.

备注/Memo

备注/Memo:
基金项目:湖南省卫生健康委员会科研计划项目(202204123255)
更新日期/Last Update: 2024-11-04